Jenny Leeds is an investor for Counterpoint Global. She joined Morgan Stanley in 2019 and has 9 years of investment experience. Prior to joining the firm, she was an associate and Equity Research Analyst at Bank of America Merrill Lynch (BAML) focused on biotechnology. Jenny received a Ph.D. in cancer biology and immunology from Memorial Sloan Kettering Cancer Center and a B.S. in biochemistry from Tufts University.